- Home
- CGON
CGON
CG ONCOLOGY INC
as 05-20-2024 2:34pm EST
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
| Founded: | 2010 | Country: | Canada |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 2.0B | IPO Year: | 2024 |
| Target Price: | $63.75 | AVG Volume (30 days): | 646.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.77 - $50.23 | Next Earning Date: | 05-09-2024 |
| Revenue: | $539,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 400% | Revenue Growth (next year): | 983.33% |
Share on Social Networks:
Stock Insider Trading Activity of CG ONCOLOGY INC (CGON)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decheng Capital Global Life Sciences Fund IV, L.P. | CGON | 10% Owner | Jan 29 '24 | Buy | $19.00 | 400,000 | $7,600,000.00 | 400,000 | SEC Form 4 |
| Song Hong Fang | CGON | Director | Jan 29 '24 | Buy | $19.00 | 263,157 | $4,999,983.00 | 613,928 | SEC Form 4 |
Latest CG ONCOLOGY INC News
CGON Breaking Stock News: Dive into CGON Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
17 days ago
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
GlobeNewswire
24 days ago
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
GlobeNewswire
a month ago
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
GlobeNewswire
2 months ago
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
GlobeNewswire
3 months ago
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
Zacks
4 months ago
MOD vs. RACE: Which Stock Is the Better Value Option?
Yahoo Finance Video
4 months ago